School of Medicine
Showing 1-10 of 37 Results
-
Laura Michele Hack
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioDr. Laura Hack is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences and Director of Novel & Precision Neurotherapeutics at the Stanford Center for Precision Mental Health and Wellness. Dr. Hack's translational research program focuses on identifying bioclinical subtypes of depression and comorbid stress-related disorders and testing mechanistically-guided treatments for these subtypes. Dr. Hack studies treatments spanning repurposed medications, such as pramipexole and guanfacine, neuromodulation techniques, ketamine, MDMA, and psilocybin.
Dr. Hack directs the Stanford Translational Precision Mental Health Clinic (STPMHC), a cutting-edge consultation clinic for patients with a primary diagnosis of depression and comorbid anxiety disorders. Providers in the clinic integrate objective measures with a patient's history and presentation to inform treatment considerations and provide insights into the biological basis of a patient's condition. These measures, which may also help reduce self-blame and foster motivation to pursue recommended treatments, include the investigational use of clinical circuit scores derived from functional magnetic resonance imaging, symptom questionnaires, objective neurocognitive assessments, pharmacogenomic testing, and laboratory work. Patients and their referring doctors receive a detailed report with an explanation of the findings and the implications for treatment.
Additionally, as Deputy Director of the Precision Neuromodulation Clinic (PNC) within the VA Palo Alto Health Care System, she specializes in delivering novel treatments, including repetitive transcranial magnetic stimulation (rTMS) and ketamine, to patients suffering from treatment-resistant depression and comorbid stress-related disorders. -
Scott S. Hall, Ph.D
Professor of Psychiatry and Behavioral Sciences (Child & Adolescent Psychiatry & Child Development)
Current Research and Scholarly InterestsMy primary area of scholarly and clinical interest is the pathogenesis of problem behaviors shown by individuals diagnosed with intellectual and developmental disabilities (IDD), particularly those with neurogenetic forms of IDD, such as fragile X syndrome, Cornelia de Lange syndrome and Prader-Willi syndrome. My work aims to both advance understanding of these disorders and to identify effective new treatment approaches for pediatric and adult patient populations by state-of-the-art methodologies, such as brain imaging, eye tracking and functional analysis to determine how environmental and biological factors affect the development of aberrant behaviors in these syndromes. The end goal of my research is to create patient-specific methods for treating the symptoms of these disorders.
-
Joachim Hallmayer
Professor of Psychiatry and Behavioral Sciences
On Partial Leave from 09/01/2024 To 08/31/2026Current Research and Scholarly InterestsPrincipal Investigator
Infrastructure to facilitate discovery of autism genes
The purpose of this project is to facilitate the discovery of the genes that contribute autism by maintaining an infrastructure which research groups studying the genetics of autism can work collaboratively. This will be
accomplished through workshops, a Virtual Private Network, and access to a database that includes phenotype and genotype data from all participating groups.
Principal Investigator
A California Population-Based Twin Study of Autism
This will address several fundamental questions: (1) What is the heritability of autism (2) What is the contribution of genetic factors to variation in symptom dimensions? (3) Is there a continuum between the quantitative neurocognitive traits and clinical disorder? (4) What proportion of the variance in the neurocognitive traits is accounted for by genetic and non-genetic factors?
Co-Investigator
Center for Integrating Ethics in Genetics Research(Cho)
The goal of this project is to serve as a center of excellence in neurogenetics research, to develop a national model for bench, to bedside research ethics consultation, and to provide training opportunity in biomedical ethics.
Co-Investigator
Gene, Brain and Behavior in Turner Syndrome(Reiss)
The primary objective of this project is to use advanced, multi-modal magnetic resonance imaging (MRI) techniques, analyses of X chromosome parent-of-origin and cognitive-behavioral assessment to elucidate the effects of monosomy and X-linked imprinting on neurodevelopment and neural function in a large cohort of young girls with Turner syndrome, pre-estrogen replacement.
Project Director
Project F: Genomic Analysis in narcolepsy cataplexy
The goal of the project is to locate genes outside the HLA region that influence susceptibility to narcolepsy. In order to localize these genes we will carry out a linkage and association study in the most extensive world-wide collection of DNAs from well-characterized patients with narcolepsy and their families. -
Bonnie Halpern-Felsher
Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.
-
Antonio Hardan, M.D.
Professor of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsThe neurobiology of autism
Neuroimaging in individuals with autism
Psychopharmacological treatment of children and adults with autism and/or developmental disorders
The neurobiology and innovative interventions of several neurogenic disorders including DiGeorge Syndrome (Velocardiofacial syndrome; 22q11.2 mutations), PTEN mutations, and Phelan McDermid Syndrome (22q13 mutations). -
Kate Hardy
Clinical Professor, Psychiatry and Behavioral Sciences
BioKate Hardy is a California Licensed Psychologist who has specialized in working with individuals with psychosis for over 20 years in both research and clinical settings. Dr. Hardy received her doctorate in clinical psychology from the University of Liverpool, United Kingdom. She has worked in specialist early psychosis services in both the UK and the US, including UCSF’s Prodrome Assessment Research and Treatment (PART) program, where she completed her post-doctoral fellowship, and as Clinical Director for the Prevention and Recovery from Early Psychosis (PREP) program. Dr. Hardy is the co-director for the INSPIRE clinic at the Department of Psychiatry and Behavioral Health, Stanford University and has significant experience in providing CBTp to individuals with early psychosis, and those at risk of developing psychosis, in both individual and group settings and integration of this clinical intervention to broader systems and staff teams. Dr. Hardy is also involved in the implementation of national strategies to increase dissemination of early psychosis models with the aim of bringing these cutting edge treatments to a broader population and is the co-editor of the book Intervening Early: A team approach.
Dr. Hardy is also the director of INSPIRE training and within this role has led multiple trainings and workshops in CBTp to a wide variety of audiences including community clinicians, psychiatrists, and families, and provides ongoing supervision and consultation in this approach. INSPIRE training offers training in evidence based interventions for psychosis to providers across diverse settings. In 2024 Dr. Hardy became president elect for IEPA: Intervening Early in Mental Health. -
Nancy A. Haug
Adjunct Clinical Professor, Psychiatry and Behavioral Sciences
BioNancy A. Haug, PhD is Adjunct Clinical Professor and Addiction Medicine fellowship program faculty in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She currently leads didactics and a journal club for Addiction Medicine fellows, and teaches a postdoctoral seminar on ethics and legal issues for the Clinical Psychology Fellowship Program. Dr. Haug's primary academic affiliation is Professor of Psychology at Palo Alto University, where she teaches, advises and supervises doctoral students in the PGSP-Stanford PsyD Consortium. Dr. Haug previously served as faculty and attending psychologist in the Department of Psychiatry at the University of California San Francisco, and taught in the University of California, Berkeley Alcohol & Drug Studies program. She obtained her PhD in Clinical Psychology and Behavioral Medicine at the University of Maryland, Baltimore County and a Master's degree in Counseling Psychology at Loyola University, Maryland. She completed a clinical internship and postdoctoral fellowship at University of California, San Francisco and San Francisco General Hospital in public service and minority mental health.
Dr. Haug is a member of the American Psychological Association (APA) Ethics Committee and formerly served as a member of the California Psychological Association Ethics Committee. She is a Fellow and Member-at-Large for Practice in the Society of Addiction Psychology (APA, Division 50). Dr. Haug is on the editorial board of the Journal of Psychoactive Drugs and the Journal of Addictive Diseases. She was funded by SAMHSA for a practitioner-education initiative to expand training for evidence-based addiction treatment. Dr. Haug leads the Harm Reduction and Addiction Treatment Laboratory at PAU with current research studies on the implementation of evidence-based practices in addiction treatment, harm reduction for substance use, cannabis vaping and psychedelic-assisted psychotherapy.
Dr. Haug has been licensed as a psychologist in California since 2004, is board certified in addiction psychology by American Board of Professional Psychology, and has an independent practice in Los Gatos, CA. She has clinical expertise in treating substance misuse and eating disorders using motivational interviewing, cognitive-behavioral and mindfulness-based therapies including Acceptance and Commitment Therapy. Dr. Haug is a Stanford WellConnect referral for fellows, residents and faculty in her clinical practice. She recently completed the Stanford YogaX 200-Hour Yoga Teacher Training Program with healthcare setting emphasis.
